|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus Everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nishino M, Sholl LM, Hodi FS, Hatabu H and
Ramaiya NH: Anti-PD-1-related pneumonitis during cancer
immunotherapy. N Engl J Med. 373:288–290. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nishino M, Giobbie-Hurder A, Hatabu H,
Ramaiya NH and Hodi FS: Incidence of programmed cell death 1
inhibitor-related pneumonitis in patients with advanced cancer: A
systematic review and meta-analysis. JAMA Oncol. 2:1607–1616.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil K, Caterino JM, Chau I, Ernstoff MS, Gardner JM,
Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
society of clinical oncology clinical practice guideline. J Clin
Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Champiat S, Lambotte O, Barreau E, Belkhir
R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M,
Durrbach A, et al: Management of immune checkpoint blockade
dysimmune toxicities: A collaborative position paper. Ann Oncol.
27:559–574. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sanchez GO, Jahn K, Savic S, Zippelius A
and Läubli H: Treatment of mycophenolate-resistant immune-related
organizing pneumonia with infliximab. J Immunother Cancer.
6(85)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Huang Y, Fan H, Li N and Du J: Risk of
immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic
review and network meta-analysis. Cancer Med. 8:2664–2674.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yamaguchi T, Shimizu J, Hasegawa T, Horio
Y, Inaba Y, Yatabe Y and Hida T: Pre-existing pulmonary fibrosis is
a risk factor for anti-PD-1-related pneumonitis in patients with
non-small cell lung cancer: A retrospective analysis. Lung Cancer.
125:212–217. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang
F, Han C, Long Y, Li Y, Zheng X, et al: Risk factors for
pneumonitis in patients treated with anti-programmed death-1
therapy: A case-control study. Cancer Med. 7:4115–4120.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kido H: Influenza virus pathogenicity
regulated by host cellular proteases, cytokines and metabolites,
and its therapeutic options. Proc Jpn Acad Ser B Phys Biol Sci.
91:351–368. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Beck KE, Blansfield JA, Tran KQ, Feldman
AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM,
Kleiner D, et al: Enterocolitis in patients with cancer after
antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J
Clin Oncol. 24:2283–2289. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Johnston RL, Lutzky J, Chodhry A and
Barkin JS: Cytotoxic T-lymphocyte-associated antigen 4
antibody-induced colitis and its management with infliximab. Dig
Dis Sci. 54:2538–2540. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sawai Y, Katsuya Y, Shinozaki-Ushiku A,
Iwasaki A, Fukayama M, Watanabe K and Nagase T: Rapid temporal
improvement of pembrolizumab-induced pneumonitis using the
anti-TNF-α antibody infliximab. Drug Discov Ther. 13:164–167.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gosset P, Perez T, Lassalle P, Duquesnoy
B, Farre JM, Tonnel AB and Capron A: Increased TNF-alpha secretion
by alveolar macrophages from patients with rheumatoid arthritis. Am
Rev Respir Dis. 143:593–597. 1991.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tanaka R, Ichimura Y, Kubota N, Saito A,
Nakamura Y, Ishitsuka Y, Watanabe R, Fujisawa Y, Kanzaki M, Mizuno
S, et al: Activation of CD8 T cells accelerates anti-PD-1
antibody-induced psoriasis-like dermatitis through IL-6. Commun
Biol. 3(571)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zen Y and Yeh MM: Hepatotoxicity of immune
checkpoint inhibitors: A histology study of seven cases in
comparison with autoimmune hepatitis and idiosyncratic drug-induced
liver injury. Mod Pathol. 31:965–973. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Minor DR, Chin K and Kashani-Sabet M: .
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab)
induced immune-related colitis. Cancer Biother Radiopharm.
24:321–325. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fishman JA, Hogan JI and Maus MV:
Inflammatory and infectious syndromes associated with cancer
immunotherapies. Clin Infect Dis. 69:909–920. 2019.PubMed/NCBI View Article : Google Scholar
|
